Latest Articles

Scientists have tested whether the diabetes drug metformin could improve survival and/or reduce the severity of common and unpleasant side effects associated with the treatment of metastatic prostate cancer.

In this fourth installment of The Gut Microbiome and Cancer: A Miniseries, we explore how harnessing microbial communities – both natural and synthetic – could help shape the future of precision cancer therapy.

For many cancers, surgical resection is the primary treatment option. However, traditional tissue analysis is slow and error-prone; point-of-care MS tools like the MasSpec Pen could improve cancer detection.

Despite the global shift toward early detection and prevention in oncology, oral cancer is still treated reactively. This article explores the emerging potential of light-based therapies that can be used in non-hospital settings.

Federated data platforms offer a solution to many of the challenges associated with advancing precision medicine with artificial intelligence.

In this Q&A, Dr. Seshadhri Subramanian of UEA discusses new research linking specific urinary and prostatic bacteria to aggressive prostate cancer. The team identified a bacterial biomarker set associated with faster disease progression.

In this third installment of our miniseries, we explore the contrasting roles of harmful and protective dietary components – such as the Western diet and red meat versus dietary fiber and polyphenols – on gut health and cancer development.

Researchers are developing new strategies to drug the undruggable in cancer, including targeting intracellular KRAS with radio-labeled antibodies and using AI and quantum computing to overcome drug resistance.

Discover how cutting-edge tools and analytics are advancing cell therapy, improving precision, safety and scalability in modern treatments.

Learn how specific miRNA signatures have potential as metastatic colorectal cancer biomarkers, enhancing non-invasive detection and patient risk stratification.